Publications by the researcher in collaboration with MARÍA AZUCENA ESPARIS OGANDO (35)

2024

  1. ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression

    International Journal of Molecular Sciences, Vol. 25, Núm. 6

2023

  1. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257

2022

  1. ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

    Cancers, Vol. 14, Núm. 14

2021

  1. Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer

    npj Precision Oncology, Vol. 5, Núm. 1

2020

  1. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

    Cancer Letters, Vol. 491, pp. 50-59

2019

  1. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

    Frontiers in Immunology, Vol. 10

  2. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

  3. MEK5 promotes lung adenocarcinoma

    The European respiratory journal

2017

  1. ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA

    Oncogene, Vol. 36, Núm. 12, pp. 1733-1744

2016

  1. Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies

    Oncotarget, Vol. 7, Núm. 29, pp. 45042-45051

  2. Targeting the EGF/HER ligand-receptor system in cancer

    Current Pharmaceutical Design, Vol. 22, Núm. 39, pp. 5887-5898

2015

  1. The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma

    Gut, Vol. 64, Núm. 9, pp. 1454-1465

2014

  1. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

    Oncogene, Vol. 33, Núm. 2, pp. 148-156

  2. Therapeutic potential of ERK5 targeting in triple negative breast cancer

    Oncotarget, Vol. 5, Núm. 22, pp. 11308-11318

2013

  1. Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue

    Stem Cells, Vol. 31, Núm. 6, pp. 1075-1085

  2. ERK5/BMK1 is a novel target of the tumor suppressor VHL: Implication in clear cell renal carcinoma

    Neoplasia (United States), Vol. 15, Núm. 6, pp. 649-659

  3. Potent antimyeloma activity of a novel ERK5/CDK inhibitor

    Clinical Cancer Research, Vol. 19, Núm. 10, pp. 2677-2687

2009

  1. ERK2, but not ERK1, mediates acquired and "De novo" resistance to imatinib mesylate: Implication for CML therapy

    PLoS ONE, Vol. 4, Núm. 7

  2. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as potential therapeutic target

    PLoS ONE, Vol. 4, Núm. 5

2008

  1. Neuregulins and cancer

    Clinical Cancer Research, Vol. 14, Núm. 11, pp. 3237-3241